ViaCyte Does it Again: Insulin Production in People with T1D
ViaCyte, a beta cell replacement company long supported by Breakthrough T1D, has shown—for the first time ever—that its PEC-Direct therapy helps people with type 1 diabetes (T1D) produce insulin again. Preliminary data from ViaCyte’s clinical trial show that when pancreatic precursor cells, called “PEC-01 cells,” are implanted under the skin and properly engrafted, they are […]
Trick or Treat: Have a scare-free and fun Halloween
To say that Halloween is ‘fun’ is an understatement! So many kids and adults look forward to this one evening of dressing up, eating as much candy as they want and partying with friends! But Halloween can be scary in more than the obvious way for families of those newly diagnosed with type 1 diabetes […]
EASD Brings World-Renowned Minds to Barcelona
For 55 years, leading researchers from around the world have gathered for the annual meeting of the European Association for the Study of Diabetes (EASD). At this year’s meeting, from September 16-20 in Barcelona, Spain, more than 50 studies were presented by Breakthrough T1D researchers, funded now or in the past, working to find cures […]
Breakthrough T1D and Beyond Type 1 Launch Alliance
Today we announced an exciting new alliance with Beyond Type 1, aimed at getting more information, more resources, and more support to our type 1 diabetes (T1D) community. This is an innovative partnership, based on a shared objective of supporting the people and families impacted by T1D with accelerated research, advocacy, and community engagement. Breakthrough […]
Breakthrough T1D Clinical Trial Results Announced at the 55th EASD Meeting
A protein, called glucokinase (or GK), acts as a key regulator of sugar levels in the body. If blood glucose levels are deemed too high, activation of GK in the liver causes the body to use more glucose, which in turn lowers glucose levels in the blood. vTv Therapeutics has developed a GK activator, called […]
The Best of the Best: Researchers Unite at the 55th EASD Annual Meeting
For 55 years, leading researchers from around the world have gathered for the annual meeting of the European Association for the Study of Diabetes (EASD). At this year’s meeting, from September 16-20 in Barcelona, Spain, more than 50 studies will be presented by Breakthrough T1D researchers, funded now or in the past, working to find […]
FDA Approves Xeris Pharmaceuticals’ Glucagon to Treat Severe Hypoglycemia
On Tuesday, the type 1 diabetes (T1D) community got a helping hand in their ability to avoid severe hypoglycemia when the Food and Drug Administration (FDA) approved the first premixed, prefilled liquid glucagon formulation that can be used with either a pre-filled syringe (GVOKE PFS) or an auto-injector (GVOKE HypoPenTM). Xeris Pharmaceuticals, which created the […]
Breakthrough T1D Launches First Center of Excellence, Aiming to Accelerate Type 1 Diabetes Research
Breakthrough T1D today launched its first Center of Excellence, a new research and funding model aimed at accelerating leading type one diabetes (T1D) research. The new Breakthrough T1D Northern California Center of Excellence will unite the work being done at Stanford University and the University of California, San Francisco, focusing on beta cell therapies and […]
Semma Therapeutics, Backed by the T1D Fund, Acquired by Major Biopharma Company
In an exciting step forward in type 1 diabetes (T1D) research and development and for people with T1D, on September 3, 2019, Semma Therapeutics agreed to be acquired by Vertex for $950 million, the largest transaction ever in a T1D cure-based therapeutic program. The T1D Fund, Breakthrough T1D’s innovative venture philanthropy fund provided a catalytic […]
Breakthrough T1D Innovative Clinical Trial Design Workshop
BMC Medicine 16: 29 (2018)
